Lusine Demirkhanyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lusine Demirkhanyan has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Christopher S. Gondi
University of Illinois Urbana-Champaign University of Illinois Urbana-Champaign University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois Chicago University of Illinois at Urbana-Champaign University of Illinois Chicago University of Illinois Urbana-Champaign
8 shared publications - Abdulhalim Salim Serafi
Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia
4 shared publications - Mohammed A. Bafail
Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia
4 shared publications - Zahir Hussain
Umm Al-Qura University, Saudi Arabia
4 shared publications - Eleonora Zakharian
Department of Cancer Biology & Pharmacology University of Illinois College of Medicine Peoria IL USA
3 shared publications - Shalan Alaamri
Department of Medicine, College of Medicine, University of Jeddah, Jeddah 21589, Saudi Arabia
3 shared publications
Latest Publications
- Open Access
- 18 April 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (4) , 417
Psychedelics and Autism Therapy: A Review of Current Research and Future Directions
Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the serotonin 5-HT2A receptor, their therapeutic effects also involve interactions with other serotonergic, dopaminergic, and glutamatergic pathways, collectively promoting neuroplasticity—the brain’s ability to change and adapt. The specific receptors’ activation leads to structural and functional changes in the brain that can enhance social behavior and emotional regulation. Studies show that psychedelics may reduce symptoms of conditions like treatment-resistant depression and PTSD, highlighting their therapeutic potential. For ASD specifically, psychedelics may improve psychological flexibility, reduce distress, and enhance social interaction. While promising, the use of these substances requires careful consideration. Psychedelics can induce intense experiences and altered states of consciousness, necessitating strict monitoring and support during therapy. Ethical guidelines, including informed consent, are crucial, especially for vulnerable populations. In conclusion, psychedelics hold significant promise for treating ASD and other psychiatric disorders by promoting neuroplasticity and modulating complex signaling pathways. Continued research and clinical trials, conducted with strong ethical oversight, are essential to realizing their full therapeutic potential.
- 18 April 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (4) , 417
Open AccessPsychedelics and Autism Therapy: A Review of Current Research and Future Directions
Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the serotonin 5-HT2A receptor, their therapeutic effects also involve interactions with other serotonergic, dopaminergic, and glutamatergic pathways, collectively promoting neuroplasticity—the brain’s ability to change and adapt. The specific receptors’ activation leads to structural and functional changes in the brain that can enhance social behavior and emotional regulation. Studies show that psychedelics may reduce symptoms of conditions like treatment-resistant depression and PTSD, highlighting their therapeutic potential. For ASD specifically, psychedelics may improve psychological flexibility, reduce distress, and enhance social interaction. While promising, the use of these substances requires careful consideration. Psychedelics can induce intense experiences and altered states of consciousness, necessitating strict monitoring and support during therapy. Ethical guidelines, including informed consent, are crucial, especially for vulnerable populations. In conclusion, psychedelics hold significant promise for treating ASD and other psychiatric disorders by promoting neuroplasticity and modulating complex signaling pathways. Continued research and clinical trials, conducted with strong ethical oversight, are essential to realizing their full therapeutic potential.
- Open Access
- 21 October 2025
- Published by Yerevan State University in Journal of Innovative Solutions for Eco-Environmental Sustainability
- p. 181
Bridging in vitro Electrophysiology and in vivo Behavior in Zebrafish Models of Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and the presence of restricted and repetitive behaviors. While the neurobiological underpinnings of ASD remain elusive, understanding the function of individual neurons and their integration into circuits is critical. The zebrafish (Danio rerio) offers a powerful model system for dissecting neural circuit function due to its genetic tractability, external development, larval transparency, and conserved neuroanatomy. This presentation highlights the utility of the zebrafish model for investigating ASD-relevant neural circuitry through a combined in vitro and in vivo approach. We focus on isolating specific neuronal populations from zebrafish models of ASD to perform in vitro electrophysiological recordings, characterizing their intrinsic electrical properties and synaptic signaling deficits at the single-cell level. These in vitro findings regarding altered neuronal excitability and connectivity are then validated in vivo by assessing corresponding behavioral phenotypes in intact zebrafish larvae using established paradigms for social interaction, locomotion, and sensory processing. By correlating cellular-level electrical dysfunction observed in vitro with circuit-level activity and complex behaviors in vivo, we aim to bridge the gap between molecular/cellular deficits and the emergent behavioral characteristics of ASD. This integrated approach using the zebrafish model provides a valuable platform for identifying specific neuronal contributions to ASD pathophysiology and offers potential avenues for high-throughput screening of therapeutic interventions targeting neuronal function. The insights gained from these studies contribute to a more comprehensive understanding of ASD neurobiology and facilitate the translation of findings towards clinical applications.
- 21 October 2025
- Published by Yerevan State University in Journal of Innovative Solutions for Eco-Environmental Sustainability
- p. 181
Open AccessBridging in vitro Electrophysiology and in vivo Behavior in Zebrafish Models of Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and the presence of restricted and repetitive behaviors. While the neurobiological underpinnings of ASD remain elusive, understanding the function of individual neurons and their integration into circuits is critical. The zebrafish (Danio rerio) offers a powerful model system for dissecting neural circuit function due to its genetic tractability, external development, larval transparency, and conserved neuroanatomy. This presentation highlights the utility of the zebrafish model for investigating ASD-relevant neural circuitry through a combined in vitro and in vivo approach. We focus on isolating specific neuronal populations from zebrafish models of ASD to perform in vitro electrophysiological recordings, characterizing their intrinsic electrical properties and synaptic signaling deficits at the single-cell level. These in vitro findings regarding altered neuronal excitability and connectivity are then validated in vivo by assessing corresponding behavioral phenotypes in intact zebrafish larvae using established paradigms for social interaction, locomotion, and sensory processing. By correlating cellular-level electrical dysfunction observed in vitro with circuit-level activity and complex behaviors in vivo, we aim to bridge the gap between molecular/cellular deficits and the emergent behavioral characteristics of ASD. This integrated approach using the zebrafish model provides a valuable platform for identifying specific neuronal contributions to ASD pathophysiology and offers potential avenues for high-throughput screening of therapeutic interventions targeting neuronal function. The insights gained from these studies contribute to a more comprehensive understanding of ASD neurobiology and facilitate the translation of findings towards clinical applications.
- Open Access
- 12 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 349
Beyond Barriers: Achieving True Equity in Cancer Care
Healthcare disparities in cancer care remain pervasive, driven by intersecting socioeconomic, racial, and insurance-related inequities. These disparities manifest in various forms such as limited access to medical resources, underrepresentation in clinical trials, and worse cancer outcomes for marginalized groups, including low-income individuals, racial minorities, and those with inadequate insurance coverage, who face significant barriers in accessing comprehensive cancer care. This manuscript explores the multifaceted nature of these disparities, examining the roles of socioeconomic status, race, ethnicity, and insurance status in influencing cancer care access and outcomes. Historical and contemporary data highlight that minority racial status correlates with reduced clinical trial participation and increased cancer-related mortality. Barriers such as insurance coverage, health literacy, and language further hinder access to cancer treatments. Addressing these disparities requires a systemic approach that includes regulatory reforms, policy changes, educational initiatives, and innovative trial and treatment designs. This manuscript emphasizes the need for comprehensive interventions targeting biomedicine, socio-demographics, and social characteristics to mitigate these inequities. By understanding the underlying causes and implementing targeted strategies, we can work towards a more equitable healthcare system. This involves improving access to high-quality care, increasing participation in research, and addressing social determinants of health. This manuscript concludes with policy recommendations and future directions to achieve health equity in cancer care, ensuring optimal outcomes for all patients.
- 12 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 349
Open AccessBeyond Barriers: Achieving True Equity in Cancer Care
Healthcare disparities in cancer care remain pervasive, driven by intersecting socioeconomic, racial, and insurance-related inequities. These disparities manifest in various forms such as limited access to medical resources, underrepresentation in clinical trials, and worse cancer outcomes for marginalized groups, including low-income individuals, racial minorities, and those with inadequate insurance coverage, who face significant barriers in accessing comprehensive cancer care. This manuscript explores the multifaceted nature of these disparities, examining the roles of socioeconomic status, race, ethnicity, and insurance status in influencing cancer care access and outcomes. Historical and contemporary data highlight that minority racial status correlates with reduced clinical trial participation and increased cancer-related mortality. Barriers such as insurance coverage, health literacy, and language further hinder access to cancer treatments. Addressing these disparities requires a systemic approach that includes regulatory reforms, policy changes, educational initiatives, and innovative trial and treatment designs. This manuscript emphasizes the need for comprehensive interventions targeting biomedicine, socio-demographics, and social characteristics to mitigate these inequities. By understanding the underlying causes and implementing targeted strategies, we can work towards a more equitable healthcare system. This involves improving access to high-quality care, increasing participation in research, and addressing social determinants of health. This manuscript concludes with policy recommendations and future directions to achieve health equity in cancer care, ensuring optimal outcomes for all patients.
- Open Access
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
The Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 406
Open AccessThe Role of Mucins in Cancer and Cancer Progression: A Comprehensive Review
Mucin, a heavily glycosylated glycoprotein, serves an important function in forming protective and immune defense barriers against the exterior environment on epithelial surfaces. While secreted-type mucins are involved in mucous production, transmembrane mucins, which contain O-glycosylated tandem repeats, play a pivotal role in cellular signaling, especially in immune modulation and mediating inflammatory response. However, dysregulation in mucin expressions, such as MUC1, MUC2, MUC4, MUC5AC, and MUC16, have been observed in many cancer cells. More specifically, alterations in the expression and glycosylation of MUC1 have been associated with the upregulation of pathways involving the cell proliferation, angiogenesis, migration, and invasion of cancer cells. With mucin’s extensive involvement in cancer biology, several mucin biomarkers, such as CA125, CA19-9, and CEA, have been utilized as diagnostic and prognostic monitoring biomarkers in ovarian, pancreatic, and colon cancer. Vaccines and antibody therapy against abnormal mucin glycosylation have also been investigated for potential therapy for mucin-related cancers that are resistant to traditional chemotherapy agents. Despite the lack of specificity in mucin biomarkers and challenges in efficient drug delivery systems, the current advancement in mucin-targeted immunotherapy highlighted the pivotal potential in developing therapeutic targets to improve cancer prognosis.
- Open Access
- 2 February 2025
- Published by MDPI AG in Pathophysiology
- Vol. 32 (1) , 7
Overweight-Related Hypertension in Middle-Aged Men Is Linked to Elevated Leptin, TNF-α, IL-6, Cholesterol, and Reduced Testosterone
Background/Objectives: One of the major causes of hypertension (HT) is the transition of normal weight (NW) status to overweight (OW) status and obesity in a population, which leads to cardiovascular disease (CVD) and other disorders. A variety of factors/variables are involved in the development of HT and OW-related hypertension (OHT). However, we planned to investigate the pathophysiological role of serum leptin (Lep), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), total cholesterol (TC) and serum testosterone (ST) in OHT in middle-aged men. Methods: We consulted three groups of middle-aged men (age: 51–60 years)—an HT group (n: 97, high normal weight (HNW), body mass index (BMI): 23–24.9 kg/m2); an OHT group (n: 97, high overweight (HOW), BMI: 28–29.9 kg/m2) and a normal control group (NC, n: 98, HNW)—to investigate the variations in and correlations of Lep, IL-6, TNF-α, ST, TC and other variables. Results: Significant variations were obtained for the comparisons of TNF-α, Lep, ST and TC for the patient groups. OHT vs. NC showed a significant difference for ST. OHT vs. NC and OHT vs. HT had significant variations for IL-6. Significant changes were obtained for the serum levels of TNF-α, Lep, IL-6, ST and TC among groups. Significant and positive linear associations were obtained for TNF-α, Lep, TC and IL-6. Significant and negative linear associations were found for ST plotted against Lep, TNF-α and IL-6. Conclusions: The current report provides pathophysiological evidence of the interactive role of serum Lep, TNF-α, ST, TC and IL-6 in middle-aged men with HT and OHT. We suggest that the changes we noted in the present study would be helpful for further BMI-based studies in various subcategories of NW, OW and obese subjects with/without HT.
- 2 February 2025
- Published by MDPI AG in Pathophysiology
- Vol. 32 (1) , 7
Open AccessOverweight-Related Hypertension in Middle-Aged Men Is Linked to Elevated Leptin, TNF-α, IL-6, Cholesterol, and Reduced Testosterone
Background/Objectives: One of the major causes of hypertension (HT) is the transition of normal weight (NW) status to overweight (OW) status and obesity in a population, which leads to cardiovascular disease (CVD) and other disorders. A variety of factors/variables are involved in the development of HT and OW-related hypertension (OHT). However, we planned to investigate the pathophysiological role of serum leptin (Lep), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), total cholesterol (TC) and serum testosterone (ST) in OHT in middle-aged men. Methods: We consulted three groups of middle-aged men (age: 51–60 years)—an HT group (n: 97, high normal weight (HNW), body mass index (BMI): 23–24.9 kg/m2); an OHT group (n: 97, high overweight (HOW), BMI: 28–29.9 kg/m2) and a normal control group (NC, n: 98, HNW)—to investigate the variations in and correlations of Lep, IL-6, TNF-α, ST, TC and other variables. Results: Significant variations were obtained for the comparisons of TNF-α, Lep, ST and TC for the patient groups. OHT vs. NC showed a significant difference for ST. OHT vs. NC and OHT vs. HT had significant variations for IL-6. Significant changes were obtained for the serum levels of TNF-α, Lep, IL-6, ST and TC among groups. Significant and positive linear associations were obtained for TNF-α, Lep, TC and IL-6. Significant and negative linear associations were found for ST plotted against Lep, TNF-α and IL-6. Conclusions: The current report provides pathophysiological evidence of the interactive role of serum Lep, TNF-α, ST, TC and IL-6 in middle-aged men with HT and OHT. We suggest that the changes we noted in the present study would be helpful for further BMI-based studies in various subcategories of NW, OW and obese subjects with/without HT.
- Open Access
- 1 January 2025
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 17 (1) , 51-59
Serum Vitamin D Level Correlates Significantly With Leptin and Tumor Necrosis Factor-Alpha in Overweight Postmenopausal Women With Hypertension
Background: Association of serum vitamin D (vitD) with leptin (Lep) and tumor necrosis factor-alpha (TNF-α) is not precisely known in overweight hypertensive (OW-HT) postmenopausal (PMP) women. Hence, the present study was carried out to investigate the body mass index (BMI)-based correlation of serum vitD with Lep and TNF-α in OW-HT PMP women. Methods: Women subjects in their early PMP (n = 346, age: 51 - 60 years) categorized into three groups had main inclusion criteria of specified range of age, BMI and blood pressure (BP). Enzyme-linked immunosorbent assay (ELISA) and other kit methods were employed to investigate the role of various variables in three subject groups (normal weight normotensive (NW-NT, n = 116, BMI (kg/m2): 22 - 24.9), normal weight hypertensive (NW-HT, n = 115, BMI: 22 - 24.9) and OW-HT (n = 115, BMI: 25 - 29.9) PMP women). Results: A significant negative linear correlation of vitD with serum Lep and TNF-α, and a significant positive linear correlation of BMI with Lep and TNF-α in OW-HT PMP women were obtained. Significantly higher levels of serum Lep, TNF-α and interleukin-6 (IL-6) were found in OW-HT PMP women, as compared to NW-HT PMP women. Conclusions: The present study suggests that decreased serum vitD levels correlate with the Lep and TNF-α in OW-HT PMP women. However, further studies may help understand the impact of vitD in cardiovascular events and the influencing factors in OW-HT PMP women.
- 1 January 2025
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 17 (1) , 51-59
Open AccessSerum Vitamin D Level Correlates Significantly With Leptin and Tumor Necrosis Factor-Alpha in Overweight Postmenopausal Women With Hypertension
Background: Association of serum vitamin D (vitD) with leptin (Lep) and tumor necrosis factor-alpha (TNF-α) is not precisely known in overweight hypertensive (OW-HT) postmenopausal (PMP) women. Hence, the present study was carried out to investigate the body mass index (BMI)-based correlation of serum vitD with Lep and TNF-α in OW-HT PMP women. Methods: Women subjects in their early PMP (n = 346, age: 51 - 60 years) categorized into three groups had main inclusion criteria of specified range of age, BMI and blood pressure (BP). Enzyme-linked immunosorbent assay (ELISA) and other kit methods were employed to investigate the role of various variables in three subject groups (normal weight normotensive (NW-NT, n = 116, BMI (kg/m2): 22 - 24.9), normal weight hypertensive (NW-HT, n = 115, BMI: 22 - 24.9) and OW-HT (n = 115, BMI: 25 - 29.9) PMP women). Results: A significant negative linear correlation of vitD with serum Lep and TNF-α, and a significant positive linear correlation of BMI with Lep and TNF-α in OW-HT PMP women were obtained. Significantly higher levels of serum Lep, TNF-α and interleukin-6 (IL-6) were found in OW-HT PMP women, as compared to NW-HT PMP women. Conclusions: The present study suggests that decreased serum vitD levels correlate with the Lep and TNF-α in OW-HT PMP women. However, further studies may help understand the impact of vitD in cardiovascular events and the influencing factors in OW-HT PMP women.
- Open Access
- 7 November 2024
- Published by MDPI AG in Preprints.org
Overweight-Related Hypertension in Middle-Aged Men: Pathophysiological Impact of Serum Leptin, TNF-α, IL-6, Cholesterol and Testosterone
The age and sex specific data of the worldwide prevalence of hypertension (HT) shows that it is an important health challenge and requires to be screened, prevented and treated with high priority. One of the major causes of HT is the transition of normal weight status to overweight (OW) status and obesity in a population that leads to cardiovascular disease (CVD) and other disorders. A variety of factors/ variables are involved in the development of HT and OW related hypertension (OHT). We proposed the present study to consult the middle-aged men (age range: 51-60 years) having HT and OHT along with normal control (NC; age range: 51-60 years) men for investigating the two samples comparisons, analysis of variance and correlations of serum leptin (Lep), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), serum testosterone (ST), total cholesterol (TC) and other variables in NC (n: 98; high normal weight BMI: 23-24.9 kg/m2, HT (n: 97; high normal weight BMI: 23-24.9 kg/m2) and OHT (n: 97; high overweight BMI: 28-29.9 kg/m2) subjects. Significant variations were obtained for the comparisons of TNF-α, Lep, ST and TC for the subject groups. The OHT vs. NC showed significant difference for ST. The OHT vs. NC and OHT vs. HT gave significant variation for IL-6. One-way ANOVA revealed significant change for TNF-α, Lep, IL-6, ST and TC levels among groups. Significant and positive linear associations were obtained for each other for TNF-α, Lep, TC and IL-6. The HT and OHT subject groups presented non-significant negative linear correlations for ST plotted against TC. Significant and negative linear association was found for ST plotted against each of Lep, TNF-α and IL-6. Conclusively, the current report provides pathophysiological evidence of the interactive role of serum Lep, TNF-α, ST, TC and IL-6 in middle-aged men with hypertension and overweight-related hypertension.
- 7 November 2024
- Published by MDPI AG in Preprints.org
Open AccessOverweight-Related Hypertension in Middle-Aged Men: Pathophysiological Impact of Serum Leptin, TNF-α, IL-6, Cholesterol and Testosterone
The age and sex specific data of the worldwide prevalence of hypertension (HT) shows that it is an important health challenge and requires to be screened, prevented and treated with high priority. One of the major causes of HT is the transition of normal weight status to overweight (OW) status and obesity in a population that leads to cardiovascular disease (CVD) and other disorders. A variety of factors/ variables are involved in the development of HT and OW related hypertension (OHT). We proposed the present study to consult the middle-aged men (age range: 51-60 years) having HT and OHT along with normal control (NC; age range: 51-60 years) men for investigating the two samples comparisons, analysis of variance and correlations of serum leptin (Lep), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), serum testosterone (ST), total cholesterol (TC) and other variables in NC (n: 98; high normal weight BMI: 23-24.9 kg/m2, HT (n: 97; high normal weight BMI: 23-24.9 kg/m2) and OHT (n: 97; high overweight BMI: 28-29.9 kg/m2) subjects. Significant variations were obtained for the comparisons of TNF-α, Lep, ST and TC for the subject groups. The OHT vs. NC showed significant difference for ST. The OHT vs. NC and OHT vs. HT gave significant variation for IL-6. One-way ANOVA revealed significant change for TNF-α, Lep, IL-6, ST and TC levels among groups. Significant and positive linear associations were obtained for each other for TNF-α, Lep, TC and IL-6. The HT and OHT subject groups presented non-significant negative linear correlations for ST plotted against TC. Significant and negative linear association was found for ST plotted against each of Lep, TNF-α and IL-6. Conclusively, the current report provides pathophysiological evidence of the interactive role of serum Lep, TNF-α, ST, TC and IL-6 in middle-aged men with hypertension and overweight-related hypertension.
- Open Access
The Multifaceted Role of miR-21 in Pancreatic Cancers
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3′ untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial–mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21’s multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial–mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.
Open AccessThe Multifaceted Role of miR-21 in Pancreatic Cancers
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3′ untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial–mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21’s multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial–mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.
- Open Access
- 21 June 2023
- Published by MDPI AG in Preprints.org
Interplay of Serum Leptin, Tumor Necrosis Factor Alpha, and Testosterone in Overweight-Related Hypertensive Men
Hypertension (HT) is a very common risk factor and a frequent cause of morbidity and mortality worldwide mainly due to much increase in overweight (OW) and obesity that manifests in various forms of cardiovascular disease (CVD). There are a number of factors that may cause overweight hypertension (OHT). However, we planned to conduct the present work to study the HT and OHT men for finding the variation, interrelationship and association of important cytokines mainly serum leptin (Lep) and tumor necrosis factor-alpha (TNF-α), serum testosterone (ST), total cholesterol (TC) and inflammatory status by measuring interleukin-6 (IL-6). Three groups of subjects, the normal controls (NC; n:98; age range: 51-60 years), HT (n: 97; age range: 51-60 years) subjects, and OHT (n: 97; age range: 51-60 years) subjects were studied. Comparisons for Lep, ST, TNF-α, IL-6 and TC levels for the subject groups showed significant variations. The ST indicated significant difference only for NC vs. OHT. The IL-6 gave significant difference for NC vs. OHT and HT vs. OHT. The one-way ANOVA showed significant difference among groups for BMI, TC, IL-6, TNF-α, ST and Lep levels. Significant positive linear correlation for all groups among Lep, TNF-α, IL-6 and TC were found. The ST against TC for HT and OHT groups presented non-significant negative linear correlations. The ST showed significant negative linear correlation with other variables. Conclusively, the present study uncovers the interactive impact of serum leptin, TNF-α, testosterone, total cholesterol and IL-6 in hypertensive and overweight-related hypertensive men.
- 21 June 2023
- Published by MDPI AG in Preprints.org
Open AccessInterplay of Serum Leptin, Tumor Necrosis Factor Alpha, and Testosterone in Overweight-Related Hypertensive Men
Hypertension (HT) is a very common risk factor and a frequent cause of morbidity and mortality worldwide mainly due to much increase in overweight (OW) and obesity that manifests in various forms of cardiovascular disease (CVD). There are a number of factors that may cause overweight hypertension (OHT). However, we planned to conduct the present work to study the HT and OHT men for finding the variation, interrelationship and association of important cytokines mainly serum leptin (Lep) and tumor necrosis factor-alpha (TNF-α), serum testosterone (ST), total cholesterol (TC) and inflammatory status by measuring interleukin-6 (IL-6). Three groups of subjects, the normal controls (NC; n:98; age range: 51-60 years), HT (n: 97; age range: 51-60 years) subjects, and OHT (n: 97; age range: 51-60 years) subjects were studied. Comparisons for Lep, ST, TNF-α, IL-6 and TC levels for the subject groups showed significant variations. The ST indicated significant difference only for NC vs. OHT. The IL-6 gave significant difference for NC vs. OHT and HT vs. OHT. The one-way ANOVA showed significant difference among groups for BMI, TC, IL-6, TNF-α, ST and Lep levels. Significant positive linear correlation for all groups among Lep, TNF-α, IL-6 and TC were found. The ST against TC for HT and OHT groups presented non-significant negative linear correlations. The ST showed significant negative linear correlation with other variables. Conclusively, the present study uncovers the interactive impact of serum leptin, TNF-α, testosterone, total cholesterol and IL-6 in hypertensive and overweight-related hypertensive men.
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 407a-408a
Crosstalk of Pain and Pleasure: TRPV1 is a Novel Oxytocin Receptor
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 407a-408a
Crosstalk of Pain and Pleasure: TRPV1 is a Novel Oxytocin Receptor